158 related articles for article (PubMed ID: 16105491)
1. Anticoagulation: new challenges, old drugs.
Olshansky B
Curr Cardiol Rep; 2005 Sep; 7(5):359-61. PubMed ID: 16105491
[TBL] [Abstract][Full Text] [Related]
2. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
3. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
4. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
5. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
6. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Reiffel JA
Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for atrial fibrillation in the elderly.
Halperin JL
Am J Geriatr Cardiol; 2005; 14(2):81-6. PubMed ID: 15785149
[TBL] [Abstract][Full Text] [Related]
8. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
10. New possibilities in anticoagulant management of atrial fibrillation.
Waldo AL
Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
[TBL] [Abstract][Full Text] [Related]
11. Ximelagatran for stroke prevention in atrial fibrillation.
Boos CJ; Lip GY
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P; Grind M; Adler J;
J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
[TBL] [Abstract][Full Text] [Related]
13. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
Scardi S; Giansante C
Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran.
Choudhury A; Goyal D; Lip GY
Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
[TBL] [Abstract][Full Text] [Related]
15. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
16. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
[TBL] [Abstract][Full Text] [Related]
17. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
Kulbertus H
Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
Halperin JL
J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
[TBL] [Abstract][Full Text] [Related]
19. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
20. Will this be the end of the anticoagulation clinic for patients with atrial fibrillation?
Mitchell AR
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):405-8. PubMed ID: 16248832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]